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Abstract
Objective—Evaluate the effects of obesity on health-related quality of life (HRQOL) measures
in juvenile-onset SLE (jSLE).
Methods—Obesity was defined as a body mass index (BMI) ≥ 95th% according to the sexspecific Center for Disease Control body mass index-for-age charts and determined in a
multicenter cohort of jSLE patients. In this secondary analysis, the domain and summary scores of
the Pediatric Quality of Life (PedsQL) Inventory and the Child Health Questionnaire (CHQ) of
obese jSLE patients were compared to those of non-obese jSLE patients as well as historical obese
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and non-obese healthy controls. Mixed-effects modeling was performed to evaluate the
relationship between obesity and HRQOL measures.
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Results—Among the 202 jSLE patients, 25% (n=51) were obese. Obesity had a significant
negative impact on HRQOL in jSLE, even after adjusting for differences in current corticosteroid
use, disease activity, disease damage, gender, and race between groups. Obese jSLE patients had
lower physical functioning compared to non-obese jSLE patients, and to non-obese and obese
healthy controls. Compared to their non-obese counterparts, obese jSLE patients also had worse
school functioning, more pain, worse social functioning, and emotional functioning. Parents of
obese jSLE patients worry more. The CHQ scores for obese jSLE patients were also worse
compared to non-obese jSLE patients in several other domains
Conclusion—Our study demonstrates the detrimental effects of obesity on patient-reported
outcomes in jSLE. This supports the importance of weight management for the therapeutic plan of
jSLE.
Key Terms
SLE; Obesity; Children
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Introduction
Obesity in children and adolescents is defined as a body mass index (BMI) that exceeds the
95th percentile of reference populations. The 2010 U.S. National Health and Nutrition
Examination Survey (NHANES) found childhood obesity had increased since 1990s to an
estimated 16.9% (1, 2). Cross-sectional studies report the prevalence of obesity among
adults with Systemic Lupus Erythematosus (SLE) at around 28% (3). Not surprisingly,
obesity in this population is associated with an added risk of cardiovascular disease,
decreased health-related quality of life (HRQOL), and higher disability (3, 4).
Corticosteroids are more commonly prescribed to children with juvenile-onset Systemic
Lupus Erythematosus (jSLE) than adults with SLE (5), which may put the former at an even
higher risk for obesity. The impact of obesity on the well-being and HRQOL of patients
with jSLE has not been well examined and is the focus of this secondary analysis using
prospective data from jSLE patients.
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Materials & Methods
Patients & visits
We used secondary data (6, 7) from 202 jSLE patients recruited from routine clinic visits at
11 pediatric rheumatology centers in the U.S. and Canada. Patients fulfilled the American
College of Rheumatology (ACR) Classification Criteria for SLE prior to the age of 16 years.
They constituted a convenience sample with follow-ups every 3 months for up to 18 months
(total visits = 815). This study was approved by the institutional review board of the
Cincinnati Children's Hospital Medical Center.
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Anthropometric measurements
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Weight (kg) and height (cm) were measured during the visits, and the BMI was calculated
[weight in kg / (height in cm)2]. In children and adolescents (age < 19 years), ‘obesity’ is
commonly defined as a BMI ≥ 95th percentile of the Sex-Specific Center for Disease Control
(CDC) 2000 BMI-For-Age Growth Charts (www.cdc.gov/growthcharts). Individuals whose
BMI is between the 85th and the 95th percentile are considered ‘overweight’ (8), while those
whose BMI is lower than the 5th percentile are regarded as ‘underweight’. A normal BMI
lies between the 5th and 85th percentile as per the Sex-Specific CDC 2000 BMI-For-Age
Growth Charts.
Health related quality of life measures
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(1) Pediatric Quality of Life Inventory (PedsQL™) is composed of a child self-report and a
corresponding parent-report for different age ranges. The PedsQL-Generic core scale
(PedsQL-GC) consists of 23-items that cover four health domains: physical, emotional,
social, and school functioning. The PedsQL-Rheumatology module (PedsQL-RM) is a
rheumatology-specific HRQOL scale comprised of 22 items encompassing five domains:
pain and hurt, daily activities, treatment, worry, and communication. The items are scored
on a 5-point Likert scale (never, almost never, sometimes, often, and always), from which
summary scores (range: 0 to 100, higher scores indicating higher HRQOL) can be
calculated. Previously published norms of the PedsQL-GC in healthy and obese children are
available and were used in this study (9).
(2) The Child Health Questionnaire P50 (CHQ™) is a generic parent-completed HRQOL
measure and yields scores (0=worst health; 100=best health) in 12 domains: physical
functioning; role/social limitations-emotional/behavioral; role/social limitations-physical;
bodily pain; behavior; general health perceptions; mental health; self-esteem; parent impactemotional; parent impact-time; family activities; and family cohesion. Additionally, the
CHQ allows for determination of Global Health, Physical Health, and Psychosocial Health
summary scores (10).
Disease characteristics and jSLE therapy
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Disease activity was assessed using the Safety of Estrogen in Lupus Erythematosus:
National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index
(SELENA–SLEDAI; range of scores: 0 - 105). For the analysis, ‘at least moderate disease
jSLE activity’ was defined as SELENA-SLEDAI summary score of > 4. Damage of organs
and tissues since the diagnosis with SLE was measured by the Systemic Lupus International
Collaborating Clinics/ACR Damage Index (SDI; range of scores: 0 – 47). For the analysis,
‘more than minimal jSLE damage’ was defined as total SDI score > 0.
Medications that were taken at the time of the study were recorded including their use of
immunosuppressive agents (i.e. mycophenolate mofetil, azathioprine, methotrexate,
cyclophosphamide, and rituximab). Intravenous methylprednisolone pulses (yes/no) and the
daily prednisone dose were also noted. For the purpose of our study, ‘current low daily
prednisone dose’ was defined as daily prednisone-equivalent dose < 5 mg and < 0.2/mg/kg/
day.
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Statistical analysis
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Logistic regression was used to determine which patient and jSLE features are significantly
associated with the presence of obesity. Possible covariates of the relationship between
obesity and HRQOL were tested (present vs. absent): age < 12 years, race (African
American vs. not), Hispanic ethnicity, gender, ‘at least moderate disease jSLE activity’,
‘more than minimal jSLE damage’, ‘current immunosuppressive use’, ‘current use of
intravenous methylprednisolone pulses’, and ‘current low daily prednisone dose’.
Mixed effects modeling was performed to determine the association of the presence of
obesity (yes/no) with the PedsQL and CHQ (summary and domain scores), while adjusting
for other relevant covariates. Covariates associated with the presence of obesity in the
univariate analyses of p-values ≤ 0.2, were considered in the multivariate mixed-effects
models.
Using two-sided independent t-test we also compared the PedsQL and CHQ summary and
domain scores of obese jSLE patients with: 1) historical healthy non-obese controls, and 2)
historical obese controls without jSLE (9).
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P-values ≤ 0.05 were considered statistically significant. Statistical analyses were done using
SAS (version 9.2; Cary, NC) and Microsoft Excel (version 2008; Redmond, WA).

Results
Patient characteristics and frequency of obesity
Table 1 summarizes the demographic and clinical characteristics of the 202 patients at the
baseline visit. The mean ± SD age was 15.4 ± 3.0 years (range: 5-20).
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The historical control groups [non-obese (N=9,565) and obese (N=63)] available for
comparison with the jSLE patients were somewhat younger. The mean age ± SD for nonobese healthy control was 9.8 ± 3.2 years (p-value <0.0001) and for obese historical controls
was 12.1 ± 3.0 years (p-value <0.0001), in comparison with 15.4 ± 2.3 years for obese jSLE
patients. There was a lower proportion of females in the non-obese healthy control (49%, pvalue <0.0001) and obese historical controls (46%, p-value =0.017), as compared to 78% in
the obese jSLE patients.
88% of patients in the obese jSLE group were Non-Hispanics. There were similar
proportions of obese jSLE patients between the Hispanic and non-Hispanic groups (21% and
26%, respectively). None of the 19 Asian jSLE patients was obese while the proportion of
obesity in African-American jSLE patients was higher than Caucasian jSLE patients (36%
vs. 23%; p = 0.06). African-American jSLE patients made up 47% of the obese group,
although they only made up 33% of the entire cohort.
Minimum follow-up for patients included was 6 months. Mean follow-up since disease
presentation was 2 years and seven months. Mean age of onset was 13 years. Mean followup was 12.3 months for non-obese jSLE patients while it was 14.3 months for obese jSLE
patients. Fifty-one patients (25%) were obese, all of whom remained obese during average
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follow-up period of 5 months. Obese and non-obese jSLE patients were similar in terms of
disease activity [mean SELENA-SLEDAI ± SD = 6.5 ± 6.4 vs. 7.9 ± 6.9; p = NS (not
significant)], age, ethnic, and gender distribution. Unexpectedly, obese jSLE patients were
treated with significantly lower daily prednisone dose than non-obese jSLE patients whether
total dose or weight adjusted dose is considered [mean (mg/day) ± SD = 20.9 ± 24.6 vs. 31.8
± 35.8, p-value = 0.05; mean (mg/kg/day) ± SD = 0.15 ±.0.18 vs. 0.32 ±.0.48, p-value
<0.0001), respectively]. Data for the cumulative dose of prednisone was not available.
Association of patient characteristics with HRQOL and presence of obesity
In univariate analyses of baseline data, African-American race (OR = 2.3; p-value = 0.01)
was significantly associated with the presence of obesity. Among jSLE patients, AfricanAmerican race was associated with lower HRQOL scores (p-value = 0.01), as was the
presence of ‘at least moderate disease jSLE activity’ (p-value = 0.02). ‘Current low
prednisone requirement’ was associated with higher HRQOL scores (p-value = 0.03).
Female gender was significantly associated with lower self-reported PedsQL-RM scores (pvalue = 0.01, Table 2).
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Differences in HRQOL between obese jSLE patients and comparison groups
We found significant differences in HRQOL scores between obese jSLE and non-obese
jSLE patients in the analyses that adjusted for group differences (i.e. corticosteroid use,
disease activity, disease damage, gender, and race) as are detailed in Table 3. The total and
domain scores of the PedsQL-GC and PedsQL-RM were all lower among obese as
compared to non-obese jSLE patients, irrespective of whether patient self-report or parentreports were considered. These differences reached statistical significance for the: (1) selfreported and parent-reported physical, emotional, and pain/hurt domains; (2) parent-reported
school functioning and worry domains; and (3) self-reported social domain (all p-values <
0.0001 to 0.047). As expected, parent-reported PedsQL-scores were generally lower than
self-reported PedsQL-scores for both the obese and non-obese jSLE groups (p-values = 0.04
- < 0.0001, data not shown).
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Obese jSLE patients had lower total and domain scores of the PedsQL-GC compared to
healthy non-obese controls and were all statistically significant except for the self-reported
emotional and social domain (all p-values < 0.0001 to 0.018).
Obese jSLE patients had lower (1) self-reported and parent-reported physical functioning
(PedsQL-GC), and (2) parent-reported school functioning than obese controls without jSLE
(p-values = 0.002 to 0.03). Conversely, self-reported social functioning was higher in obese
jSLE patients as compared to the obese controls without SLE (p-value = 0.009).
When considering the CHQ to measure HRQOL, we found that the domain and summary
scores of the CHQ were generally lower in obese jSLE patients compared to non-obese
jSLE patients, reaching statistical significance for global health, physical functioning, role/
social limitations-emotional/behavioral, general health perceptions, parent impact–time,
family activities, and family cohesion domains (p-values= 0.007 -0.039, Table 3).
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Our exploratory analysis also suggested that being overweight (BMI 85th-95th percentile)
did not significantly affect HRQOL scores (data not shown).
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Discussion
Obesity is known to be associated with decreased HRQOL and increased disability in adults
with SLE (4). In this study, we report a significant negative impact of obesity on the
HRQOL of children and adolescents with jSLE, with physical function being most
consistently impaired. School function and pain/hurt domains were also negatively affected
by the presence of obesity in jSLE. The detrimental effects of obesity were independent of
current corticosteroid use (i.e. prednisone dose and use of methylprednisolone pulses),
disease activity, disease damage, gender, and race.
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Our previous research showed that jSLE patients as a group have lower physical functioning
domain scores compared to healthy children (11). This study builds on this earlier report and
suggests that this is especially true for obese jSLE patients. The physical functioning is the
most negatively affected HRQOL domain, irrespective of the measure (PedsQL and CHQ)
used. Underlying this observation may be changed body mechanics, alignment, and mobility
in obese individuals (1). Of note, our data did not support that there were differences in
disease activity specific to the musculoskeletal system between obese and non-obese jSLE
patients (data not shown).
Our previous research also found jSLE patients to have lower school functioning compared
to healthy children (11). Our current study suggests that this decrement is even larger in
obese jSLE than non-obese jSLE patients. These findings are in line with previous
observation among groups of children without jSLE, in which obese children's cognitive
functioning was lower, mostly due to poorer visuospatial organization and general mental
ability as compared to their non-obese counterparts (12). No data is available at the present
time to assess the association of obesity and cognitive dysfunction in jSLE but an
association has been shown in aSLE (13).
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Likewise, we found that obese jSLE patients reported more impairments of pain on HRQOL
(PedsQL-RM) than non-obese children with jSLE. This appears to be of particular relevance
since obesity is also associated with the development of pain amplification syndromes in
adults with SLE (14).
Interestingly, social and emotional functioning domain scores are lower in jSLE obese
compared to non-obese jSLE patients and healthy controls but not in comparison with the
obese group without SLE. Although reasons for this observation are not entirely clear, it
may be that obese children without jSLE do not receive the same social support as obese
children with jSLE. Moreover, being overweight did not impact HRQOL as obesity did, and
may reflect a threshold effect of obesity.
There are several limitations to our study. The jSLE patients included in our study
constituted a convenience sample and therefore our data are unsuited to estimate the
prevalence of obesity in jSLE in the U.S. The demographics of patients included in our
study, however, are comparable to other Northern American jSLE cohorts. The available
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historical controls also had some differences with the jSLE group in terms of distributions of
sex, age, and ethnicity but these were taken into account in the analyses as potential
covariates for HRQOL and presence of obesity. It is also unlikely that we measured all
possible confounders in our adjusted analyses but we did adjust for all covariates that have
been previously shown to affect HRQOL in jSLE (11). We were also unable to assess the
impact of duration of corticosteroid use on obesity and impact of duration of obesity on
HRQOL. Finally, as done by others, we defined obesity based on BMI which is an imperfect
albeit the most commonly used measure of body fat in the clinical setting.
In summary, our study demonstrates the detrimental effects of obesity on many aspects of
HRQOL in jSLE, particularly impairing physical functioning. These observations deserve
consideration in designing meaningful outcomes of weight management programs in jSLE.
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69.2 ± 2.8

80.6 ± 2.8

69.9 ± 3.2

89.4 ± 1.9

95.9 ± 1.7

80.7 ± 3.3

79.1 ± 1.8

84.0 ± 2.5

80.0 ± 2.9

85.9 ± 1.8

94.0 ± 1.9

77.5 ± 3.3

85.6 ± 1.7

74.6 ± 2.7

89.0 ± 2.2

82.3 ± 2.7

80.9 ± 3.0

81.4 ± 2.2

77.4 ± 2.7

87.7 ± 2.6

80.4 ± 2.6

81.6 ± 3.1

81.7 ± 2.3

NS

NS

NS

NS

<0.0001

0.043

NS

0.013

NS

NS

0.005

0.007

NS

0.047

0.016

0.0003

0.003

0.0003

NS

0.032

0.0004

<0.0001

81.1 ± 0.2

85.2 ± 0.2

79.3 ± 0.2

87.5 ± 0.2

83.8 ± 0.2

78.8 ± 0.2

83.7 ± 0.2

81.3 ± 0.2

84.5 ± 0.2

82.7 ± 0.2

Non-obese (N=9,565)¶

Obese (N=51)

P-value (A vs.B)*

C

B
Non - obese
(N=151)

A

Physical Functioning

Generic Core Scale: Parent-Report

Pediatric Quality of Life Questionnaire

Health Related Quality of Life Measures

jSLE

0.0005

NS

NS

<0.0001

0.0004

<0.0001

0.018

<0.0001

<0.0001

<0.0001

D

75.0 ± 1.8

72.6 ± 2.3

68.6 ± 2.3

77.5 ± 2.3

74.0 ± 1.8

76.6 ± 2.1

73.5 ± 2.2

72.6 ± 2.2

76.3 ± 2.2

75.0 ± 1.8

Obese¶¶ (N=63)

ND ŦŦŦ

P-value (A vs. C)
**

Historical controls without jSLE

NS

0.009

NS

0.030

NS

0.002

NS

NS

0.025

NSŦŦ

P-value (A vs.D)***
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70.4 ± 4.3
56.5 ± 4.2
76.8 ± 2.4
42.1 ± 2.2
73.3 ± 2.2
51.1 ± 4.4
56.6 ± 3.8
66.1 ± 3.8
68.4 ± 2.9
67.9 ± 3.4

Bodily Pain

Behavior

Generic Health Perceptions

Mental Health

Self Esteem

Parent Impact-Emotional

Parent Impact-Time

Family Activities

Family Cohesion

0.029

0.050

0.007

NS

NS

NS

0.036

NS

NS

NS

0.039

0.002

NS

0.006

NS

0.038

ND

P-value (A vs. C)
**
Obese¶¶ (N=63)

D
P-value (A vs.D)***

Historical controls. For PedsQL-Generic Module: healthy pediatric patients with no chronic illness (N=9,565) (9)

¶

P-value from 2-sided t-test comparing HRQOLscores from A (obese jSLE) vs. D (obese non-jSLE)

P-value from 2-sided t-test comparing HRQOL scores from A (obese jSLE) vs. C (healthy controls)

***

**

P-value from adjusted mixed effects models with summary and domain scores of HRQOL measures as dependent variable and presence of obesity (yes/no) as independent variable. Models adjusted for ‘at
least moderate disease activity’ (SELENA-SLEDAI scores ≤ 4 or not), ‘current low daily prednisone dose’ (< 0.2 mg/kg/day and < 5 mg/day or not), race (African American or not), gender, and ‘more
than minimal disease damage’ (total SLICC-DI scores=0 or not)

*

74.9 ± 3.0

73.8 ± 2.6

75.8 ± 3.3

53.1 ± 3.5

47.6 ± 3.9

76.6 ± 2.0

46.4 ± 1.9

79.9 ± 2.1

56.5 ± 3.7

76.2 ± 3.9

79.3 ± 3.1

75.7 ± 3.3

45.0 ± 0.9

37.8 ± 1.6

78.6 ± 2.7

54.4 ± 2.6

Values are mean ± standard error of the mean (SEM); for details, please refer to Table 1

Ŧ

Legend:

72.5 ± 3.4

Role/Social Limitations-Physical

44.3 ± 1.4

Psychosocial Function Score

Role/Social Limitations-Emotional/Behavioral

33.1 ± 1.8

Physical Function Score

64.5 ± 3.9

74.3 ± 3.0

Global Behavior

Physical Functioning

47.8 ± 3.2

Non-obese (N=9,565)¶

Non - obese
(N=151)

Obese (N=51)

Global Health

Childhood Health Questionnaire

C

B

A
P-value (A vs.B)*
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ŦŦŦ
ND- comparison data are not available

NS- not significant

ŦŦ

¶¶
Historical controls. Obese pediatric patients without rheumatologic disease (N=63) (9)
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